cas 1131-62-0|| where to buy 1-(3,4-Dimethoxyphenyl)ethanone

Produktname:1-(3,4-Dimethoxyphenyl)ethanone

IUPAC Name:1-(3,4-dimethoxyphenyl)ethan-1-one

Packungseinheit	Verfügbarer Vorrat	Preis($)	Menge
CM247812-500g	in stock	ŵȡ

Nur für den Einsatz in Forschung und Entwicklung..

Anfrage-Formular

Chemische Bezeichnung

CAS-Nummer

Menge*

Erforderliche Spezifikationen*
(Gehalt %, Materialqualität etc.)

Name des Ansprechpartners*

E-Mail des Ansprechpartners*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 1131-62-0 regularly via the above email.

Zusätzliche Hinweise

Verification code*

refresh

: CAS-Nr.:1131-62-0; Molekulare Formel:C10H12O3; Schmelzpunkt:-; SMILES-Code:CC(C1=CC=C(OC)C(OC)=C1)=O; Dichte:

: Katalognummer:CM247812; Molekulargewicht:180.2; Siedepunkt:287°C at 760 mmHg; Mdl-Nr.:MFCD00008737; Lagerung:Store at room temperature.

: Benzenes; Benzene is an important organic compound with the chemical formula C6H6, and its molecule consists of a ring of 6 carbon atoms, each with 1 hydrogen atom. Benzene is a sweet, flammable, colorless and transparent liquid with carcinogenic toxicity at room temperature, and has a strong aromatic odor. It is insoluble in water, easily soluble in organic solvents, and can also be used as an organic solvent itself. The ring system of benzene is called benzene ring, and the structure after removing one hydrogen atom from the benzene ring is called phenyl. Benzene is one of the most important basic organic chemical raw materials. Many important chemical intermediates can be derived from benzene through substitution reaction, addition reaction and benzene ring cleavage reaction.

: Cabozantinib; On August 21, 2023, Exelixis and Ipsen announced that the global phase 3 CONTACT-02 study of cabozantinib (Cabometyx ®) in combination with atezolizumab for metastatic castration-resistant prostate cancer (mCRPC) met the primary endpoint of progression-free survival (PFS) in an interim analysis.
Prostate cancer is the fourth most common cancer worldwide and the second most common cancer among men. At present, the drugs approved for the treatment of CRPC are basically AR inhibitors or PARP inhibitors, and the combination therapy of Cabozantinib + Atezolizumab is expected to become a new treatment option for such patients.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.